Newsletter | November 20, 2018

11.20.18 -- Novartis Turns To Digital Technologies For Clinical Trials

 
From The Editor

Greetings Cell & Gene Readers,

 

From AI to IoT to machine learning, new and innovative technologies are making their way into clinical trials. But which have the greatest potential to transform studies? Read how Novartis turns to digital technologies for clinical trials.

 

The FDA published a new draft guidance on August 10, 2018, entitled, Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics. The comment period for the draft guidance closed on October 12, 2018, and approximately 20 comments were submitted to the docket. Several key themes emerged across the comments submitted to the docket. Samantha Eakes of Greenleaf Health explains lists and explains these themes in “Key Takeaways From FDA’s New Guidance On First-In-Human Multiple Expansion Cohort Trials.”

 

Finally, from all of us at Cell & Gene, we wish you and yours a Happy Thanksgiving.

 

Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Workflow For Primary Human NK Cell Isolation, Xeno-Free Expansion, Harvest, And Cryopreservation
Application Note | GE Healthcare Life Sciences

This article demonstrates the feasibility of xeno-free NK cell expansion and closure of key unit operations.

Making Novel Therapies A Reality Part 1
Article | MilliporeSigma

Cell therapy, gene therapy, and RNA-based therapies. Right now, these are the classes of therapies we’re considering novel. If you look at it historically, ten years ago recombinant proteins and monoclonal antibodies would have been novel therapies, but now they’ve become very much standardized. So now that bar has moved a little bit, and the novel therapies are really cell and gene therapies, and, to a certain extent, the RNA therapies.

Connect With Cell & Gene:
      Twitter